Related Experiment Video
Updated: Aug 11, 2026

A Rapid Strategy for the Isolation of New Faustoviruses from Environmental Samples Using Vermamoeba vermiformis
Published on: June 4, 2016
Veronate (Inhibitex)
1University of Virginia Health System, Department of Pediatrics, Charlottesville 22908, USA. DAK4R@virginia.edu
Inhibitex, under license from BioResearch, is developing Veronate, an antibody-based immunotherapy for the potential prevention of Staphylococcus epidermidis, Staphylococcus aureus and Candida infections in very-low-birth-weight infants. Phase III clinical trials of Veronate are ongoing.
Inhibitex, under license from BioResearch, is developing Veronate, an antibody-based immunotherapy for the potential prevention of Staphylococcus epidermidis, Staphylococcus aureus and Candida infections in very-low-birth-weight infants. Phase III clinical trials of Veronate are ongoing.
Related Concept Videos
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Enzyme Inhibition
Inhibitors of Bacterial DNA Synthesis
Inhibitors of Bacterial Protein Synthesis

